Takeda completed the localization of the production of Advate (Octocog alpha) medicine, intended for the treatment of patients with hemophilia A, at the Moscow-based Biocad plant. This was told to Kommersant in the Japanese company.
They explained that the parties had organized the release of the finished dosage form of the medicine, as well as the primary packaging. The parties do not disclose the amount of investments in the localization.
Octocog alpha is purchased by the Ministry of Health within the framework of the State Program of Twelve High-Cost Nosologies. The registration certificate for Advate is owned by SJ Biotech, a joint venture of Generium and the Irish Shire. Takeda acquired Shire in 2018, as Advate became part of the Japanese company’s portfolio.
Cooperation with Takeda confirms the high level of performance of Biocad, says the SJ Biotech general director Dmitry Morozov. The CEO of Takeda in Russia, Andrei Potapov, noted that cooperation will contribute to improving access of Russian patients to the necessary therapy.
However, it is reported that the drug may become more accessible to a large number of patients only if the Ministry of Health increases the volume of its purchases, and this requires either an increase in funding, or a decrease in the drug’s cost. Thus, the deputy general director of Stada CIS, Ivan Glushkov, assumes that, despite the product localization and due to the absence of analogues, the Advate price on the Russian market will not change. According to him, the parties’ investments in technology transfer were minimal – 10-20 million rubles, since the equipment necessary for the production of this drug was already installed at the Biocad plant.